Skip to content

Effect of mindfulness on anxiety and depression in insomnia patients: A systematic review and meta-analysis

Hangyu Li, Wanli Qin, Nannan Li, Shixing Feng, Junqi Wang, Yuan Zhang, Tianyi Wang, Chenlu Wang, Xuanyi Cai, Wen Sun, Yang Song, Dongran Han, Yixing Liu

Frontiers in Psychiatry March 2, 2023 DOI: 10.3389/fpsyt.2023.1124344 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review and meta-analysis Randomized Peer reviewed
Sample size 1,058
Population People with insomnia and anxiety-depressive symptoms
Intervention Mindfulness therapy
Duration 4–12 weeks
Topics Anxiety Depression Meditation
Keywords Insomnia Meta-analysis
Key findings Adding 4–12 weeks of mindfulness therapy to conventional treatment significantly reduced depression and anxiety scores in people with insomnia and anxiety-depressive symptoms.

Abstract

BackgroundAs a common clinical symptom, insomnia has a high incidence of combined mental illness and it is also a risk factor for the development of depression, anxiety and suicide. As a new concept in the field of health in recent years, mindfulness therapy can improve insomnia, anxiety and depression, which is a new way to solve such diseases.ObjectiveThis study aims to systematically evaluate the effects of mindfulness compared with conventional treatment on scores of the Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS) in people with insomnia and anxiety-depressive symptoms.MethodsArticles published before October 2022 were searched from seven databases and included in randomized controlled trials (RCTs) to evaluate mindfulness therapy. The assessment tool of Cochrane bias risk was used to evaluate the methodological quality of the literature. The main outcome indicators were HAMD and HAMA scores, and the secondary outcome indicators were SDS and SAS scores.ResultsTen randomized controlled trials including 1,058 subjects were systematically evaluated and meta-analyzed in this study. In the main outcome indicators, there was a significant difference between mindfulness therapy and conventional treatment in reducing HAMD score (MD: −3.67, 95% CI: −5.22–2.11, p < 0.01) and HAMA score (MD: −3.23, 95% CI: −3.90–2.57, p < 0.01). In the secondary outcome indicators, mindfulness therapy also showed a significant difference in reducing SDS scores (MD: −6.49, 95% CI: −6.86–6.11, p < 0.01) and SAS scores (MD: −7.97, 95% CI: −9.68–6.27, p < 0.01) compared with conventional treatment.ConclusionFor the people with insomnia, anxiety and depression, the use of conventional treatment with the addition of 4–12 weeks of mindfulness treatment can significantly improve anxiety and depression symptoms of patients. This is a new diagnosis and treatment idea recommended for insomniacs with or without anxiety and depression symptoms. Due to the methodological defects in the included study and the limited sample size of this paper, more well-designed randomized controlled trials are needed for verification.

Comparable studies

Other systematic reviews and meta-analyses on anxiety, most cited first.

Study Year Design Participants
Meditation Programs for Psychological Stress and Well-being Diverse adult clinical populations 2014 Meta-analysis n = 3,515
Research Review: The effects of mindfulness‐based interventions on cognition and mental health in children and adolescents – a meta‐analysis of randomized controlled trials Children and adolescents 2018 Systematic review and meta-analysis n = 3,666
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Patients with cancer- or illness-related anxiety and depression, major depressive... 2020 Systematic review n = 188
Does Mindfulness Meditation Improve Anxiety and Mood Symptoms? A Review of the Controlled Research Clinical populations with medical and emotional disorders 2007 Systematic review n = 15
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Patients from included clinical trials 2016 Systematic review

Citations in the library

Explore topics